2 stocks that could be slammed by Donald Trump

Donald Trump’s policies are looking like very bad news for these two UK companies.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Donald Trump has undoubtedly been a net positive for equities in the US. The new president’s talk of lower taxes, lower regulation and an economic stimulus programme breathed new life into the shares of banks, energy producers and builders alike. But on this side of the Atlantic I have my fears that Trump’s bombastic attacks on certain industries leaves several UK stocks in danger of being hugely negatively affected by his potential policies.

First up is speciality drug producer Shire (LSE: SHP). What worries me about Trump and Shire is that the he’s been quoted in the press as saying things such as “the pricing has been astronomical” and “you folks [drug companies] have done a very great job over the years but we have to get the prices down.

And Trump could definitely do something about bringing down drug prices either through direct legislation or giving government-run medical programmes the ability to negotiate their prices with drug makers. This is a common sense move that has somehow escaped Congress’s attention thus far.

This is a problem for all drug makers but is an extra worry for Shire as the company’s business model is based on developing drugs for rare diseases and then charging very, very high prices for the treatment.

Aside from concerns that its products may fetch lower prices, I’m also worried because Shire has taken on a whopping $23bn in net debt to fund a series of huge acquisitions that have made it a world leader in rare disease treatments. If the company’s ambitious sales and profit targets are met this won’t be a major problem, but should Trump take an axe to pharmaceutical prices, it certainly would be.

Rough seas ahead for global trade?

Also at risk of becoming collateral damage to Trump’s policies is ship broker Clarkson (LSE: CKN). It has already seen profits drop in the past year as a slowdown in demand for oil & gas-related ships and an oversupply of cargo vessels have led to low prices for bulk shipping.

The threat from Trump to Clarkson is if the new president embarks on his much-talked-about plan to impose tariffs on trading partners such as Mexico or, more worryingly, China. Were Trump to slap import taxes on goods from China, the Chinese would undoubtedly retaliate, threatening to send the volume of trade between these important partners plummeting.

This would be a problem for Clarkson because its broking services account for more than 85% of underlying pre-tax profits and would be negatively impacted should volumes and the price of cargo shipping fall.

The upside is that as a broker, Clarkson doesn’t own any ships and is paid a commission per deal arranged, so is somewhat protected from any downturn. Indeed, the company has weathered problems in the offshore oil & gas industry with aplomb and remains solidly profitable and has a cash-heavy balance sheet.

But with shares of the company trading hands at a lofty 25 times forward earnings would-be investors would do well to image the potential threat from Trump’s policies before buying shares.

Are you looking for Trump-resistant shares?

Ian Pierce has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Down 15%, are Lloyds shares simply too cheap to miss now?

Have the wheels come off the long-term growth story for Lloyds Bank shares, or are they dipping into bargain territory…

Read more »

Business manager working at a pub doing the accountancy and some paperwork using a laptop computer
Investing Articles

Are investors taking a massive gamble by chasing the BP share price higher?

Investors who thought the BP share price would continue to rocket as the Iran war intensifies may have been surprised…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

Down 23%, consider this FTSE 250 share that’s boosted profit forecasts!

This FTSE 250 tech share's leapt 8% on Wednesday (18 March) after it raised full-year profit forecasts. Is now the…

Read more »

Woman riding her old fashioned bicycle along the Beach Esplanade at Aberdeen, Scotland.
Investing Articles

4 reasons the Rolls-Royce share price might be headed to £24

Could the Rolls-Royce share price double from around £12 to closer to £24? Here are a few reasons why it…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

How much passive income can you earn by investing £20,000 in a Stocks and Shares ISA?

With dividend yields up to 10%, REITs might be some of the top passive income opportunities for UK investors in…

Read more »

Group of friends meet up in a pub
Investing Articles

Diageo shares are back at 2012 levels. Time to consider buying?

Diageo shares have fallen around 65% from their highs and now trade at levels not seen for well over a…

Read more »

Investing Articles

Softcat: a FTSE 250 tech stock offering growth, dividends and value

Right now, the share price of FTSE 250 IT company Softcat is well off its highs. And at current levels,…

Read more »

Black woman using smartphone at home, watching stock charts.
US Stock

3 huge pieces of news that could impact the Nvidia share price

Jon Smith talks through some key reveals and implications for the Nvidia share price from the company conference taking place…

Read more »